A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

NCT04007588 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Melanoma Stage III
Melanoma Stage IV

Interventions

DRUG: Nivolumab
DRUG: BMS-986205
DRUG: Ipilimumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]